The recent publication by the Levine group of the National Institutes of Health (NIH) 1 reporting that pharmacologic concentrations of ascorbic acid selectively kill cancer cells has received worldwide attention. The reason for this is that vitamin C (ascorbic acid, ascorbate) is a relatively cheap, nontoxic nutrient with a history of being used as a therapeutic tool against cancer. Nevertheless, this history has been full of controversy. The classical controversy was between Linus Pauling (Linus Pauling Institute) and Charles Moertel (Mayo Clinic). Varied results were published by the different camps, which initiated a seemingly never-ending debate. The reality is that the studies were not done the same way. Moertel never replicated the Pauling experiments. The most critical point is that both studies used oral doses of about 10 g, but Pauling also used the intravenous route. These oral doses were not high enough to reach plasma concentrations needed for vitamin C to achieve antineoplastic activity.
Another more recent modern controversy has ensued with vitamin C and conventional cancer treatment. There has been a concern that vitamin C might reduce the effectiveness of chemotherapy and radiation by reducing the potency of the free radicals necessary for killing the cancer cells. This misconception was due in part to an article published by Golde's group at Memorial Sloan Kettering in 1999 in which they described how cancer cells acquire and concentrate vitamin C. 2 They suggest that these intracellular concentrations of ascorbate may provide malignant cells with a "metabolic advantage." This published suggestion has been embraced by most practitioners without any question or further evaluation, although no data demonstrating this suggestion has been published. In contrast, a vast body of literature challenging these suggestions has been published and was summarized by Lamson and Brignall. [3] [4] [5] Moss also published a book reviewing this subject in detail. 6 The study by Levine and his group validates our earlier results published in 2002 in which we demonstrated in vitro antineoplastic activity by high-dose ascorbic acid. 7 In addition to this in vitro study, we have also published an in vivo study with guinea pigs 8 and a report on clinical cases 9 also showing antineoplastic activity with high-dose vitamin C. In addition, we also published a comprehensive review on the topic, 10 and more recently, the first clinical trial on the safety of high-dose intravenous vitamin C on terminal cancer patients was accepted for publication and will be available in January 2006.
We are very excited with the results of the NIH. We believe this may lead to a new era in research, education, and healing in an integrated manner. We also think these reports may advance the goal of our cancer research initiative, the RECNAC II project, aimed at the development of effective, nontoxic cancer therapies. We believe that by changing the biochemical conditions that promote, develop, and sustain the malignant state, we can inhibit malignant cell proliferation, increase aerobic metabolism, and achieve redifferentiation. Our research indicates that vitamin C is just one of various substances that can have a selective effect in modulating cancer cell metabolism either toward redifferentiation or apoptosis. There is much research to do, but the emerging light makes the future look brighter. The RECNAC II project was inspired and supported by the late Hugh D. Riordan, a medical maverick from the Center for the Improvement of Human Functioning (The Bright Spot for Health) in Wichita, Kansas. Dr Riordan and his son Neil pioneered the use of high-dose intravenous vitamin C in cancer patients.
